Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT02952612
Other study ID # KC16OISI0414
Secondary ID
Status Recruiting
Phase N/A
First received October 31, 2016
Last updated November 5, 2016
Start date October 2016
Est. completion date October 2021

Study information

Verified date November 2016
Source Seoul St. Mary's Hospital
Contact Jeonghoon Ha, MD
Phone +82-2-2258-6372
Email hajhoon@catholic.ac.kr
Is FDA regulated No
Health authority Korea: Ministry for Health and Welfare
Study type Observational

Clinical Trial Summary

Papillary thyroid microcarcinoma are small thyroid cancer measuring 1cm or less. Most of this tumor are not palpable and are identified either through pathologic examination or from imaging modalities, such as CT scan or thyroid sono. Active surveillance of papillary microcarcinoma is to observe thyroid papillary cancer without immediate surgical approach. The purpose of this study is to understand more about the characteristics of papillary microcarcinoma, which has been known for "the cancer slowly progression"


Recruitment information / eligibility

Status Recruiting
Enrollment 300
Est. completion date October 2021
Est. primary completion date October 2017
Accepts healthy volunteers No
Gender Both
Age group 18 Years and older
Eligibility Inclusion Criteria:

1. < 1 cm solitary nodule

2. Surrounded by = 2 mm normal thyroid parenchyma

3. Subcapsular locations not adjacent to surrounding structures, recurrent laryngeal nerve, trachea, or carotid artery

4. No evidence of invasion to surrounding structures, recurrent laryngeal nerve, trachea or carotid artery

5. No extrathyroidal extension

6. Clinically N0 and Clinically M0

7. = 18 years

8. Combined severe comorbidities or Inoperable condition (optional)

9. No wish to surgery and Willingness to accept active surveillance

10. No history of radiotherapy on head and neck area

11. Accepted by the Board of Thyroid Cancer Meeting

Exclusion Criteria:

1. = 1 cm nodule and multifocal nodules regardless of size

2. Papillary thyroid carcinoma variants associated with poor prognosis (tall cell variant, columnar variant, hobnail variant) or other types of thyroid cancer)

3. Subcapsular locations adjacent to surrounding structures, recurrent laryngeal nerve, trachea or carotid artery

4. Evidence of invasion to surrounding structures, recurrent laryngeal nerve, trachea or carotid artery

5. Extrathyroidal extension

6. Any of N1 or M1

7. Documented increase in size according to America Thyroid Association (ATA) guideline in a previously confirmed Papillary thyroid microcarcinoma

8. < 18 years

9. Not willing to accept observational active surveillance approach

Study Design

Observational Model: Case-Only, Time Perspective: Prospective


Locations

Country Name City State
Korea, Republic of Seoul St Mary's Hospital Seoul Seocho-Gu

Sponsors (1)

Lead Sponsor Collaborator
Dong Jun Lim

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type Measure Description Time frame Safety issue
Primary Progression of papillary thyroid microcarcinoma Using thyroid sonography, check any changes in size and shape of papillary thyroid microcarcinoma 5 years after enrollment No
See also
  Status Clinical Trial Phase
Completed NCT06439745 - More Than 50% of the Patients With Clinically Unifocal T1b/Small T2 Node Negative Papillary Thyroid Carcinoma Scheduled for Thyroid Lobectomy May Require Completion Thyroidectomy if the Nodal Status is Evaluated
Recruiting NCT05247476 - Type 2 Deiodinase Gene Polymorphism and the Treatment of Hypothyroidism Caused by Thyroidectomy in Thyroid Cancer Patients. Phase 4
Completed NCT04594720 - Circulating Biomarkers to Identify Thyroid Cancer
Terminated NCT04644315 - A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Phase 2
Recruiting NCT04396912 - Post-thyroidectomy Vocal Cord Paralysis Along With Hypocalcemia: STROBE - Guided Prospective Cohort
Enrolling by invitation NCT04411290 - Malignancy Predictors, Bethesda and TI-RADS Scores Correlated With Final Histopathology in Thyroid Diseases
Completed NCT03037385 - Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors Phase 1/Phase 2
Recruiting NCT06254859 - Intraoperative Neuromuscular Monitoring and Its Impact on Pre- and Postoperative Acoustic Outcomes in Thyroid Surgery
Recruiting NCT05768178 - DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Phase 2/Phase 3
Completed NCT06068101 - Clinical and Genetic Investigation of the Association Between Primary Aldosteronism and Thyroid Cancer
Completed NCT04462471 - Vemurafenib Plus Copanlisib in Radioiodine-Refractory (RAIR) Thyroid Cancers Phase 1
Recruiting NCT04985604 - Tovorafenib (DAY101) Monotherapy or in Combination With Other Therapies for Patients With Melanoma and Other Solid Tumors Phase 1/Phase 2
Recruiting NCT05796960 - European Multicenter Study on Surgical Management of Advanced Thyroid Cancer
Completed NCT01659385 - Leptin Levels in Papillary Thyroid Cancer
Completed NCT02418390 - The Efficacy and Safety of Prophylactic Central Lymph Node Dissection in Papillary Thyroid Carcinoma N/A